Show simple item record

dc.contributor.authorGreen, Melanie M
dc.contributor.authorHiley, Crispin T
dc.contributor.authorShanks, Jonathan H
dc.contributor.authorBottomley, Ian C
dc.contributor.authorWest, Catharine M L
dc.contributor.authorCowan, Richard A
dc.contributor.authorStratford, Ian J
dc.date.accessioned2009-06-19T13:39:03Z
dc.date.available2009-06-19T13:39:03Z
dc.date.issued2007-01-01
dc.identifier.citationExpression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. 2007, 67 (1):84-90 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016
dc.identifier.pmid17189065
dc.identifier.doi10.1016/j.ijrobp.2006.08.077
dc.identifier.urihttp://hdl.handle.net/10541/71038
dc.description.abstractPURPOSE: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. METHODS AND MATERIALS: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score > or =6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. RESULTS: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. CONCLUSION: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents.
dc.language.isoenen
dc.subjectCancer Proteinsen
dc.subjectProstatic Canceren
dc.subject.meshAged
dc.subject.meshDisease-Free Survival
dc.subject.meshHumans
dc.subject.meshLinear Models
dc.subject.meshMale
dc.subject.meshNeoplasm Proteins
dc.subject.meshPrognosis
dc.subject.meshProstate
dc.subject.meshProstatic Neoplasms
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.subject.meshVascular Endothelial Growth Factor A
dc.titleExpression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pharmacy and Pharmaceutical Sciences, Coupland III, University of Manchester, Oxford Road, Manchester, UK.en
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen
html.description.abstractPURPOSE: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. METHODS AND MATERIALS: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score > or =6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. RESULTS: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. CONCLUSION: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents.


Files in this item

This item appears in the following Collection(s)

Show simple item record